KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Obligations AnnualCost Of SalesDistribution Revenue By SegmentDistribution Revenue By Segment AnnualEmployee StatisticsEurope Revenue By CategoryEurope Revenue By Category AnnualFacility Count By RegionGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Income Taxes By RegionInternational Markets Revenue By CategoryInternational Markets Revenue By Category AnnualInventories BreakdownLicensing Arrangements Revenue By SegmentLicensing Arrangements Revenue By Segment AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %North America Revenue By CategoryNorth America Revenue By Category AnnualOpex As A % Of RevenueOPEX SegregationOther Revenue By SegmentOther Revenue By Segment AnnualPharmaceutical Manufacturing SitesProperty, Plant And Equipment By Geographical LocationProperty, Plant & Equipment BreakdownRevenue By Businesss Vertical AnnualRevenue By Businesss Vertical Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By CustomerRevenue By Customer %Revenue By Major ProductsRevenue By Major Products %Revenue By Major Products AnnualRevenue By Major Products Annual %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Sale Of Goods Revenue By SegmentSale Of Goods Revenue By Segment AnnualSegment ProfitSegment Profit AnnualSegment Profit Margin %Segment Profit Margin Annual %Square Footage By RegionWorkforce Headcount By Region
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gross Profit (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Gross Profit for 10 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 25.18% year-over-year to $2.7 billion, compared with a TTM value of $8.9 billion through Dec 2025, up 10.84%, and an annual FY2025 reading of $8.9 billion, up 10.84% over the prior year.
  • Gross Profit was $2.7 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $2.3 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $2.7 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2023.
  • Average Gross Profit over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2021.
  • The sharpest move saw Gross Profit fell 13.66% in 2022, then surged 36.5% in 2023.
  • Year by year, Gross Profit stood at $2.1 billion in 2021, then dropped by 13.66% to $1.8 billion in 2022, then surged by 36.5% to $2.4 billion in 2023, then decreased by 12.21% to $2.1 billion in 2024, then increased by 25.18% to $2.7 billion in 2025.
  • Business Quant data shows Gross Profit for TEVA at $2.7 billion in Q4 2025, $2.3 billion in Q3 2025, and $2.1 billion in Q2 2025.